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A commentary on
NLRP3-inflammasome activating DAMPs
stimulate an inflammatory response in
glia in the absence of priming which
contributes to brain inflammation after
injury
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Brough D (2012). Front Immunol 3:288.
doi:10.3389/ fimmu.2012.00288
The sterile inflammatory response that
occurs following acute brain insults such
as stroke, hemorrhage, or trauma is detri-
mental and largely contributes to the inci-
dence of neurodegeneration (1). Thus,
like in all organs, inflammation may
switch from a protective/homeostatic role
to a destructive effect also in the cen-
tral nervous system (CNS). Inflammation-
mediated neurotoxicity occurs as a conse-
quence of glial cell dysregulation and over-
activation: while moderate CNS damage
evokes protection by microglia, intensive
acute activation renders these cells harm-
ful, potentially impairing neuronal activ-
ity (2). Although much evidence indicates
that the IL-1 system is involved in this
adverse process, the expression, regulation,
and role of NLRP3-inflammasome in the
CNS are poorly understood (3). In par-
ticular, studies on inflammasome activa-
tion by damage associated molecular pat-
terns (DAMPs) released following brain
injury have been hindered so far by the
failure to induce inflammasome activation
under completely sterile conditions, that is,
without a priming stimulus by pathogen
products (pathogen associated molecular
patterns, PAMPs).
In their interesting article, Savage and
coworkers (4) show that DAMPs such
as ATP, monosodium urate, and calcium
pyrophosphate dehydrate crystals induce
the production of IL-6, CXCL1, and pro-
teases by glial cells but have no effect on
the expression of IL-1α or IL-1β. Remark-
ably, they also show that the acute phase
protein serum amyloid A (SAA) acts as a
priming stimulus driving levels of IL-1β
expression comparable to those induced by
lipopolysaccharide. Therefore, an endoge-
nous stress protein such as SAA, which
we can define a DAMP-like molecule,
primes glial cells, and allows other DAMPs
to activate the inflammasome and conse-
quently the secretion of IL-1β. Thus, the
first merit of this study is the demonstra-
tion that IL-1β secretion may be induced
by DAMPs via activation of the NLRP3-
inflammasome on glial cells in the absence
of an initial priming stimulus by PAMPs,
that is, in a condition of purely sterile
inflammation.
The excellent study of Savage and
coworkers is also important as it stresses
that inflammatory responses in the brain
may be influenced by both local DAMPs
and circulating inflammatory mediators.
In fact, although in the absence of injury
the brain is protected by the blood brain
barrier (BBB), which keeps microglia iso-
lated from potential blood-derived prim-
ing stimuli, the acute inflammatory event
itself causes the early breakdown of the
BBB by glia-produced proteases, allowing
the penetration of circulating inflam-
matory mediators into the brain. These
include SAA that is strongly upregulated
in blood at the same time as disrup-
tion of BBB occurs, and acts as a prim-
ing factor for IL-1β production in glial
cells.
It is worth stressing that the BBB break-
down not only allows the passage of serum
components, but also of circulating cells
including monocytes. A series of recent
studies [reviewed in Ref. (2)] indicate
that blood-derived monocytes in injured
brain perform crucial roles that cannot be
accomplished by microglia, their resident
counterparts. According to this view when
glial cells can no longer provide protection,
monocytes are recruited to the damaged
CNS; there, they work not as microglial
replacements but rather as assistant cells
that carry out activities that resident glial
cells are not (anymore) able to perform.
The definition of the different pro- and
anti-inflammatory properties of glia and
blood-derived macrophages, including the
repertoire of produced cytokines, would
be of great help for our understanding of
the acute inflammatory response in the
brain.
An additional relevant finding came
from the in vivo experiments in IL-1α/β
double KO mice, which showed that IL-1
is required for IL-6 and CXCL1 production
after cerebral ischemia. Therefore, in acute
brain injury the contribution of DAMPs
to brain inflammation occurs at various
levels: by directly stimulating the produc-
tion of pro-inflammatory mediators by
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glial cells, by contributing to BBB injury
through induction of release of various
proteases, and by triggering IL-1 release
from primed cells. Then IL-1 markedly
enhances damage-induced inflammatory
responses.
The observations reported in this
article raise a number of stimulating
questions. Some of these concern the
mechanism(s) of inflammasome activa-
tion in brain. While the key role of K+
and Ca2+ flux modulations in activat-
ing NLRP3-inflammasome in peripheral
monocytes/macrophages is widely recog-
nized, whether similar fluctuations are also
required to activate inflammasome in glial
cells is unclear. The different microenvi-
ronment may represent a problem since
in the brain Na+, K+, Ca2+ concentra-
tions must be tightly regulated as inward
and outward transport of these ions con-
trols neuron excitation. Strong ion fluxes
such as those described in activated mono-
cytes/macrophages could be detrimental
for neuron survival. Along this line, a
previous study reported that microglia,
in response to pattern recognition recep-
tor engagement by certain stimuli, enter
an overactivated state and release reac-
tive oxygen species (ROS) that cause neu-
rotoxicity (5). In monocyte/macrophages,
inflammasome activation requires a redox
signaling with both ROS and antioxi-
dant systems implicated in the correct
out come of the process (6). Likewise,
ROS and the consequent redox signaling
may play a role in inflammasome activa-
tion also in the brain. Thus, the involve-
ment of ROS produced by overactivated
microglia in this process deserves further
investigations.
Finally, an obvious extension of these
studies will be the search of the con-
ditions that promote cytokine-mediated
neuronal degeneration over survival. An
important issue is which cytokines of the
IL-1 family are produced by glial cells.
Among them, IL-18 is of particular inter-
est since like IL-1β is processed by the
NLRP3-inflammasome, is induced follow-
ing physical/emotional stress and triggers
microglial activation (7). Also the produc-
tion of IL-1Ra is highly relevant, since ele-
vation of IL-1Ra is of key importance for
quenching the inflammatory response at
the IL-1R1 as part of an autoregulatory
loop (8). A different level of production
of this cytokine by microglia and infiltrat-
ing blood-derived monocytes might also
explain the different role of these cell pop-
ulations in acute brain injury. Like in other
inflammatory diseases, induction, or phar-
macological application of IL-1Ra may be
beneficial in neurotrauma and save neu-
rons from the toxic effects of overactivated
microglia.
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